Cassava SciencesSAVA
Market Cap: $1.46B
About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Employees: 29
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
173% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 22
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
4% more funds holding
Funds holding: 141 [Q1] → 146 (+5) [Q2]
0.98% more ownership
Funds ownership: 26.83% [Q1] → 27.82% (+0.98%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
26% less call options, than puts
Call options by funds: $14.6M | Put options by funds: $19.6M
30% less capital invested
Capital invested by funds: $235M [Q1] → $165M (-$70.6M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Rodman & Renshaw Elemer Piros 60% 1-year accuracy 3 / 5 met price target | 252%upside $107 | Buy Reiterated | 8 Aug 2024 |